Tissue Regenix Group PLC Grant of share options (5437X)
May 05 2021 - 1:00AM
UK Regulatory
TIDMTRX
RNS Number : 5437X
Tissue Regenix Group PLC
05 May 2021
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Grant of share options
Tissue Regenix (AIM: TRX), the regenerative medical devices
company, announces that Daniel Lee, Chief Executive Officer, and
David Cocke, Chief Financial Officer, have each been granted an
award of restricted share units ("RSUs") with respect to ordinary
shares in the capital of the Company ("Ordinary Shares") under the
existing Tissue Regenix Share Incentive Plan.
Daniel Lee has been awarded 28,321,603 RSUs and David Cocke has
been awarded 14,649,105 RSUs, where each RSU that vests shall
represent the right to receive payment of one Ordinary Share. The
exercise price of the RSUs is 0.1p per Ordinary Share. The RSUs are
subject to continued service over a period of three years and
satisfaction of customary performance conditions relating to growth
in total shareholder return, annual revenue targets, annual
profitability targets and personal performance targets.
Following the grant of these options, Daniel Lee and David Cocke
hold options over a total of 28,321,603 and 14,649,105 RSUs
respectively representing 0.4% and 0.2% of the current issued share
capital respectively.
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44(0)20 7710 7600
and Broker)
Ben Maddison / Alex Price
Walbrook PR Ltd Tel: +44 (0)20 7933 8780
Alice Woodings / Paul McManus TissueRegenix@walbrookpr.com
About Tissue Regenix ( www.tissueregenix.com )
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or worn-out body parts. Current
applications address many critical clinical needs such as sports
medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and soft tissue scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, foot & ankle, dental, and sports medicine surgical
procedures.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities ("PDMRs") and persons
closely associated ("PCA") with them.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Daniel Lee
--------------------- -------------------------------------------
2 Reason for the notification
------------------------------------------------------------------
a) Position/status CEO
--------------------- -------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------
a) Name Tissue Regenix Group plc
--------------------- -------------------------------------------
b) LEI 213800PNOD5UHQUFJI36
--------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description Restricted share units ("RSUs") with
of the financial respect to ordinary shares in the capital
instrument, of the Company of 0.1p
type of instrument
--------------------- -------------------------------------------
b) Identification GB00B5SGVL29
code
--------------------- -------------------------------------------
c) Nature of the Issue of options
transaction
--------------------- -------------------------------------------
d) Price(s) and Volume(s):
volume(s) 28,321,603 RSUs
Price: 0.1 pence per RSU
--------------------- -------------------------------------------
d) Aggregated
information 28,321,603
- Aggregated GBP28,321.60
volume
- Price
--------------------- -------------------------------------------
e) Date of the 4 May 2021
transactions
--------------------- -------------------------------------------
f) Place of the Outside of a trading venue
transaction
--------------------- -------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name David Cocke
--------------------- -------------------------------------------
2 Reason for the notification
------------------------------------------------------------------
a) Position/status CFO
--------------------- -------------------------------------------
b) Initial notification Initial notification
/Amendment
--------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------
a) Name Tissue Regenix Group plc
--------------------- -------------------------------------------
b) LEI 213800PNOD5UHQUFJI36
--------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description Restricted share units ("RSUs") with
of the financial respect to ordinary shares in the capital
instrument, of the Company of 0.1p
type of instrument
--------------------- -------------------------------------------
b) Identification GB00B5SGVL29
code
--------------------- -------------------------------------------
c) Nature of the Issue of options
transaction
--------------------- -------------------------------------------
d) Price(s) and Volume(s):
volume(s) 14,649,105 RSUs
Price: 0.1 pence per RSU
--------------------- -------------------------------------------
d) Aggregated
information 14,649,105
- Aggregated GBP14,649.10
volume
- Price
--------------------- -------------------------------------------
e) Date of the 4 May 2021
transactions
--------------------- -------------------------------------------
f) Place of the Outside of a trading venue
transaction
--------------------- -------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDKQBQDBKBOPK
(END) Dow Jones Newswires
May 05, 2021 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024
